allogeneic cardiosphere-derived cells (CDCs)

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. Its lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy (DMD). Capricor also leverages its proprietary StealthX™ exosome platform focused on vaccinology and targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics.

Read more

cell and exosome-based biologyclinical developmentexosome engineeringmanufacturingprocess and analytical development